Balance of power shifts with Merck’s Keytruda first-line therapy approval in lung cancer

The balance of power in the anti-PD-L1 therapy duel has once again shifted with a first-line therapy win by Keytruda for non-small cell lung cancer…
Read the full story: MedCity News